# Risk Factors for Candidemia in ICU

Dr Prakash Shastri MD, FRCA Sir Ganga Ram Hospital New Delhi



## **IFI in ICU - Challenges**

### **Magnitude of Problem**

- Crude mortality  $\geq$  50-70% and attributable mortality  $\geq$  40%
- IFI 85% Candida, 15% other fungi

### Delay in antifungal therapy leads to increased mortality


- Every hour of delay 7.5% increase
- 12-24 hour delay Two fold increase

### Early diagnosis is often elusive

- Non-specific manifestations
- Culture based microbial diagnosis is poorly sensitive and slow
- Non-culture based techniques are not yet standardised for ICU patients

## **ICU Blood Isolates :**

Jan 2008 - Dec, 2010 (n = 2299)



# Candidemia is the 4th most common cause of nosocomial blood stream infections accounting for a high mortality

Table 1. Rank order of nosocomial bloodstream pathogens and the associated crude mortality among 49 hospitals throughout the United States.


Rank	Pathogen	No. of isolates	%	Crude mortality (%)
1	Coagulase-negative staphylococci	3,908	31.9	21
2	Staphylococcus aureus	1,928	15.7	25
3	Enterococci	1,354	11.1	32
4 <	Candida species	934	7.6	40
5	Escherichia coli	700	5.7	24
6	Klebsiella species	662	5.4	27
7	Enterobacter species	557	4.5	28
8	Pseudomonas species	542	4.4	33
9	Serratia species	177	1.4	26
10	Viridans streptococci	173	1.4	23

**Clinical Infectious Diseases 1999;29:239–44** 

### Mortality due to infections in febrile neutropenia

55.276 episodes Mean costs per episode: US\$19,110

mortality



Kuderer et al. Cancer 2006; 106:2258-2266

Adult Intensive Care Patients	Neonatal and Pediatric Intensive Care Patients
Prolonged length of stay High acuity Diabetes Renal failure Hemodialysis Broad-spectrum antibiotics Central venous catheter Parenteral nutrition Immunosuppressive drugs Cancer and chemotherapy Severe acute pancreatitis <i>Candida</i> colonization at multiple sites Surgery Transplantation	In addition to the adult risk factors Prematurity Low APGAR score Congenital malformations

APGAR, American Pediatric Gross Assessment Record.

## **Risk Factors**

Two main factors predispose to infections with *Candida spp.:* 

colonization of skin and mucous membranes with Candida

alteration of natural host barriers (wounds, surgery, and insertion of indwelling intravascular and urinary catheters)

## **Other Risk Factors**

Colonization with *Candida also induced by profound alteration of the endogenous* flora resulting from prolonged broad-spectrum antibiotic therapy

loss of integrity of skin and mucosal barriers - surgery (especially of the abdominal compartment)

Total parenteral nutrition, acute renal failure, haemodialysis and treatment with immunosuppressive agents

Dimopoulos G, Karabinis A, Samonis G, Falagas ME: Candidemia in immunocompromised and immunocompetent critically ill patients: a prospective comparative study. *Eur J Clin Microbiol Infect Dis 2007, 26:377-384.* 

## **Candida Score**

A prospective, cohort, observational, multicentre study that included 73 medical-surgical ICUs in Spain 'Candida score' was developed

Aim to initiate antifungal therapy early.

An adjusted logit model indicated a *Candida score* of 2.5 or more were 7.5 times more likely to have *Candida infections than patients with a score of less* than 2.5

Leon C et al.: A bedside scoring system ('*Candida score'*) for early antifungal treatment in nonneutropenic critically ill patients with *Candida colonization*. *Crit Care Med 2006, 34:730-737*.

## **Candida Score**

### Variable

Surgery on ICU admission No Yes Total parenteral nutrition No Yes Severe sepsis

No Yes

Candida species colonization No Yes

### **Score >2.5**

will help intensivists

select patients who will

benefit from early anti-

fungal administration.

Crit Care Med 2006 Vol. 34, N0.3

# **Ostrosky's Score**

Most recently, an analysis of risk factors in 2,890 patients who stayed in the ICU for more than 4 days led to the development and validation of a clinical prediction rule for the early diagnosis of invasive candidiasis in the ICU

a combination of the following factors: any systemic antibiotic presence of central venous catheter and at least two other risk factors, including total parenteral nutrition, major surgery, pancreatitis, any use of steroids and use of immunosuppressive agents. This prediction rule exhibited a sensitivity of 34%, a specificity of 90%, a positive predictive value of 10% and a negative predictive value of 97%.

Ostrosky-Zeichner L, Sable C, Sobel J, Alexander BD, Donowitz G, Kan V, Kauffman CA, Kett D, Larsen RA, Morrison V, et al.: Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. *Eur J Clin Microbiol Infect Dis 2007*, 26:271-276.

# colonization index (CI)

In the past, researchers have tried to predict infection by measuring the Candida colonization of distinct body sites (upper respiratory or stomach samples, urine and wound swabs) divided by the number of sites tested, which became known as the colonization index (CI) Although the negative predictive value was 100%, the positive predictive value for candidaemia was relatively low (66%) and could only be improved if the CI was corrected by quantitative culture

Pittet D, Monod M, Suter PM et al. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994; 220: 751–8.


## Candidemia

Recent concern has centered around the increasing proportion of candidemia episodes caused by non*albicans Candida* spp. given their association with fluconazole resistance

Ostrosky-Zeichner L, Pappas P: Invasive candidiasis in the intensive care unit. *Crit Care Med 2006; 34:857–863* Pfaller MA, Diekema DJ: Epidemiology of invasive candidiasis: A persistent public health problem. *Clin Microbiol Rev 2007; 20:* 133–163

## **Increasing isolation of non albicans Candida**

#### Candida species (% of isolates)



Clin Infect Dis. 2004;39(3):309.

Continuing Medical Education Article

# Candidemia in nonneutropenic critically ill patients: Risk factors for non-*albicans Candida* spp.

E. Geoffrey Playford, MBBS, MMed, FRACP, FRCPA; Deborah Marriott, MBBS, FRACP, FRCPA; Quoc Nguyen, BMedSci, MHA; Sharon Chen, PhD, FRACP, FRCPA; David Ellis, PhD; Monica Slavin, MD, FRACP; Tania C. Sorrell, MD, FRACP

Crit Care Med 2008 Vol. 36, No. 7 2035

### **Risk Factors for Non Albicans species**

A prospective nationwide surveillance of all episodes of candidemia occurring within Australia (the Australian Candidemia Study) was undertaken over a 3-yr period (August 2001 to July 2004)

183 episodes of ICU-acquired candidemia in 183 patients were reported from 37 ICUs.

Candida albicans	111 (62%)
C. glabrata	32 (17.9%)
C. parapsilosis	14 (7.8%)
C. tropicalis	<i>10</i> (5.6%)
C. krusei	7 (3.9%)
C. Dubliniensis	<i>02</i> (1.1%)
unidentified <i>Candida</i> spp.	02 (1.1%)

C. curvata, C. famata, and C. lusitaniae one each (0.5%).

Independently significant variables associated with nonalbicans candidemia included prior exposure to systemic antifungal agents prior gastrointestinal surgical procedures, increasing age, and intravenous drug use.

## Identify patients for Empirical Antifungal Therapy

## **Consider Empirical Antifungal**

- Persistent Fever without obvious source
- Fever not responding to antibiotics
- Positive serological marker (beta D Glucan)
- Candida colonisation of multiples sites in patient at risk of candidemia

## **Azole Prophylaxis**

## No effect on mortality in medical / surgical ICU :

Study or sub-category	Treatment n/N	Control n/N	RR (random) 95% CI	Weight %	RR (random) 95% Cl
Eggimann [17]	7/23	10/20		12.12	0.61 [0.29, 1.30]
Garbino [15]	40/103	41/101	-	47.75	0.96 [0.68, 1.34]
Jacobs [13]	2/14	13/20	<b>←−</b> −−−1	4.17	0.22 [0.06, 0.83]
Pelz [16]	14/130	16/130		15.01	0.88 [0.45, 1.72]
He [19]	2/22	3/23		2.57	0.70 [0.13, 3.78]
Sandven [18]	4/53	8/56		5.56	0.53 [0.17, 1.65]
Ables [20]	12/60	11/59		12.82	1.07 [0.51, 2.24]
Total (95% CI)	405	409		100.00	0.82 [0.62, 1.08]
Total events: 81 (Treatment	nt), 102 (Control)		-		
	i <sup>2</sup> = 6.45, df = 6 (P = 0.37), l <sup>2</sup> =	= 7.0%			
Test for overall effect: Z =					
			0.1 0.2 0.5 1 2	5 10	
				73855	
			Favours treatment Favours co	ntrol	

Andrew F. Shorr et al. Fluconazole prophylaxis in critically ill surgical patients: A meta analysis Crit Care Med 2005 Vol. 33, No. 9

# Candidemia in surgical ICU (SICU)

The burden of fungemia appears particularly high in surgical patients.

A recent prospective, observational study reported that the incidence of fungemia in surgical ICU (SICU) patients approached ten cases per 1,000 admissions higher risk because of their underlying severity of illness, impaired gastrointestinal mucosal integrity, and frequency of treatment with both broad-spectrum antibiotics and parenteral nutrition

Blumberg HM, Jarvis WR, Soucie JM, et al: Risk factors for candidal bloodstream infections in surgical intensive care unit patients: The NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. *Clin Infect Dis 2001; 33:177–186* 

## **Indications for Candida Prophylaxis**

- High risk patient
  - Neutropenic
  - Solid organ transplant
  - BMT
  - Fluconazole : 400 mg ( 6 mg/kg) daily
  - Posaconazole : 200 mg three times /day
  - Echinocandin

## Risk factors for IC

#### **Host factors**

- Extremes of age
- Neutropenia and Immunosuppression
- Diabetes and Renal failure
- Higher APACHE II score ≥ 20
- Trauma ISS >20 and burn >50%
- Bowel perforation/Disruption of physiological barriers in the digestive tract
- Colonisation of several body sites and Candiduria >10<sup>5</sup> cfu/ml

Non-Specific to support start of prophylactic or pre-emptive treatment without knowing their true value

Crit Care Med 2010; 38[Suppl.]:S380 -S387

# **ICU related Recommendations**

### USA – IDSA 2009

- Empirical\* antifungal therapy should be considered for critically ill patients with risk factors for IC
  - clinical risk factors
  - serologic markers
  - colonisation data cultures from non-sterile sites

Europe – 2011 Congress of Clinical Microbiology and Infectious Diseases

- Risk factors are not specific
- Prediction rules can be helpful in "ruling out" IC
- Serial ß–glucan measurements may also help with early diagnosis

Pre-emptive antifungal therapy is justified in high risk sub-groups of ICU patients with severe sepsis

SSG Critical Care Medicine 32(11 Suppl):S495-512, 2004

#### **Independent Risk factors for Candidiasis**

Study	Design	Odds Ratio - Multivariate	Comments
Candida colonization Charles et al (2005) Pelz et al (2001) Pittet et al. (1994)	Prosp Coh Prosp Coh Prosp Coh	OR: 18.80;Cl:5.21-67.79 OR: 10.64; Cl: 1.43-78.74 OR: 4.01; Cl: 2.16 – 7.45	Colonization index Cl> 0.50 Sites other than blood
Antibiotic use Wesse-Mayer et al. (1987) Wey et al. (1989)	Matc Case Cont Matc Case Cont	OR : 1.74; Cl: NS OR : 12.50; Cl: 2.95 – 52.91	3-5 agents
Central Venous catheters Wey et al. (1989) Blumberg et al. (2001)	Matc Case Cont Prosp Coh	OR : 7.23; Cl: NS OR: 5.40; Cl: 1.20-23.60	Hickman catheter Catheter and prior surgery
Parenteral nutrition Pelz et al. (2001) Weese-Mayer et al. (1987) MacDonald et al. (1998)	Prosp Coh Matc Case Cont Matc Case Cont	NS NS NS	Hyperalimentation with lipids Hyperalimentation

Study	Design	Odds Ratio - Multivariate	Comments
Surgery Blumberg et al. (2001) Petri etla. (1997) Renal failure Blumberg et al. (2001) Wey et al. (1989)	Prosp Coh Prosp Coh Prosp Coh Matc Case Cont	OR: 7.30; Cl: 1.00 – 53.80 NS OR: 3.83; Cl: 2.10-8.30 NS	Any type of surgery Abdominal drainage
Mechanical ventilation Wey et al. (1989) Weese-Mayer et al. (1987)	Matc Case Cont Matc Case Cont	NS NS	Duration 1-7 days Tracheal intubation
Length of Stay Wey et al. (1989)	Matc Case Cont	NS	
Severity of disease Pelz et al. (2001) Pittet et al. (1994)	Prosp Coh Prosp Coh	OR : 1.02; Cl: 1.01-1.04 OR: 1.03; Cl: 1.01-1.05	APACHE III point APACHE II point

## Conclusion

Invasive candidiasis is a serious condition in ICU patients that requires early and appropriate management in order to reduce morbidity and mortality.

The wide use of antifungal prophylaxis or screening is generally not recommended, although it may be of benefit for a highly selective small group of high-risk patients



#### Dilemma

- Culture based treatment may result in therapy started too late
- Over-interpretation of the clinical risk factors
  - problems and costs associated with needless treatments

### Challenge

 To find out the right strategy which balances out the risks and benefits for prophylaxis and pre-emptive treatment based on clinical risk factors, surveillance data and serum/BAL markers



Thank you for your attention